Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 5,400 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were bought at an average cost of $6.46 per share, for a total transaction of $34,884.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $19,825,423.46. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, July 17th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were acquired at an average price of $6.04 per share, with a total value of $10,872.00.
  • On Friday, July 14th, Phillip Md Et Al Frost bought 12,600 shares of Opko Health stock. The shares were acquired at an average price of $6.16 per share, with a total value of $77,616.00.
  • On Wednesday, July 12th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The shares were acquired at an average price of $6.12 per share, with a total value of $22,032.00.
  • On Monday, July 10th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The shares were acquired at an average price of $6.19 per share, with a total value of $309,500.00.
  • On Thursday, July 6th, Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock. The shares were acquired at an average price of $6.29 per share, with a total value of $157,250.00.
  • On Monday, July 3rd, Phillip Md Et Al Frost bought 60,800 shares of Opko Health stock. The shares were acquired at an average price of $6.44 per share, with a total value of $391,552.00.
  • On Friday, June 30th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The shares were acquired at an average price of $6.58 per share, with a total value of $23,688.00.
  • On Wednesday, June 28th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were acquired at an average price of $6.87 per share, with a total value of $12,366.00.
  • On Tuesday, June 27th, Phillip Md Et Al Frost bought 21,800 shares of Opko Health stock. The shares were acquired at an average price of $6.77 per share, with a total value of $147,586.00.
  • On Monday, June 26th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were acquired at an average price of $6.97 per share, with a total value of $12,546.00.

Opko Health, Inc. (NASDAQ:OPK) traded up 3.349% during trading on Friday, hitting $6.635. 2,069,066 shares of the stock were exchanged. The firm’s market cap is $3.71 billion. The stock’s 50-day moving average price is $6.48 and its 200-day moving average price is $7.57. Opko Health, Inc. has a 12-month low of $5.99 and a 12-month high of $12.15.

Opko Health (NASDAQ:OPK) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.02. The firm had revenue of $296.10 million during the quarter, compared to analyst estimates of $313.36 million. Opko Health had a negative return on equity of 2.13% and a negative net margin of 3.60%. The business’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.02) earnings per share. On average, equities analysts expect that Opko Health, Inc. will post ($0.20) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 5,400 Shares” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/21/opko-health-inc-nasdaqopk-ceo-phillip-md-et-al-frost-buys-5400-shares.html.

A number of institutional investors have recently modified their holdings of OPK. Vanguard Group Inc. raised its position in shares of Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock valued at $210,576,000 after buying an additional 1,112,843 shares during the last quarter. BlackRock Inc. raised its position in Opko Health by 11,481.3% in the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock worth $181,163,000 after buying an additional 22,449,752 shares in the last quarter. State Street Corp raised its position in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after buying an additional 3,138,685 shares in the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its position in Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock worth $40,489,000 after buying an additional 1,944,549 shares in the last quarter. Finally, Norges Bank purchased a new position in Opko Health during the fourth quarter worth approximately $30,421,000. 23.65% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have issued reports on OPK. Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research report on Friday. Jefferies Group LLC restated a “hold” rating and set a $8.00 target price on shares of Opko Health in a research report on Monday, June 12th. Barrington Research lifted their target price on shares of Opko Health to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $19.50 target price on shares of Opko Health in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded shares of Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $14.72.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.